Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimal design and validation of antiviral siRNA for targeting hepatitis B virus.

Acta pharmacologica Sinica - 1 Dec 2008

Fu Jie, Tang Zhong-ming, Gao Xin, Zhao Fan, Zhong Hui, Wen Mao-rong, Sun Xiao, Song Hai-feng, Qian Xiao-hong

Abstract excerpt

AIM: Optimal design of antiviral short-interfering RNA (siRNA) targeting highly divergent hepatitis B virus (HBV) was validated by quantitative structure activity relationship (QSAR) analysis. METHODS: The potency of 23 synthetic siRNAs targeting 23 sites throughout HBV pregenomic RNA were evaluated at 10 nmol/L by determining the inhibition on the expression of S/P/pregenomic mRNA and hepatitis B surface antigen...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Genome, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B e Antigens

Share to Hepatitis B Surface Antigens

Share to Hepatitis B virus

Share to Open Reading Frames

Share to Quantitative Structure-Activity Relationship

Share to RNA, Small Interfering

Source

Identifiers

PMID: 19026173
DOI: 10.1111/j.1745-7254.2008.00891.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimal design and validation of antiviral siRNA for targeting hepatitis B virus.PMID 19026173Read ↗

In Silico Design and Experimental Validation of siRNAs Targeting Conserved Regions of Multiple Hepatitis C Virus Genotypes.Semantic proximity Read ↗

In Silico and In Vitro development of novel small interfering RNAs (siRNAs) to inhibit SARS-CoV-2Semantic proximity Read ↗

In silico prediction and experimental validation of siRNAs targeting ORF1ab of MERS-CoV in Vero cell lineSemantic proximity Read ↗

Investigational RNA Interference Agents for Hepatitis BSemantic proximity Read ↗

RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant.Semantic proximity Read ↗

Evaluation of Interfering RNA Efficacy in Treating Hepatitis B: Is It Promising?Semantic proximity Read ↗

RNA Interference inhibits hepatitis B virus of different genotypes in vitro and in vivo.Semantic proximity Read ↗

RNA Interference Therapeutics for Chronic Hepatitis B: Progress, Challenges, and Future ProspectsSemantic proximity Read ↗

Control of Hepatitis B Virus with Imdusiran, a Small Interfering RNA TherapeuticSemantic proximity Read ↗

Biochemistry-informed design selects potent siRNAs against SARS-CoV-2Semantic proximity Read ↗

<em>In silico</em> Prediction and Cytotoxicity Evaluation of siRNAs Targeting Conserved Regions of MERS-CoV in Cell CultureSemantic proximity Read ↗

An in silico analysis of effective siRNAs against COVID‐19 by targeting the leader sequence of SARS‐CoV‐2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.